BioMarin Pharmaceutical has signed an agreement to acquire Lead Therapeutics to gain the latter’s early stage poly (ADP-ribose) polymerase (PARP) inhibitor, LT-673. BioMarin is hoping to develop the drug for the treatment of patients with rare and genetically-defined cancers.